The cost-effectiveness of lipid lowering in patients with diabetes: Results from the 4S trial

Diabetologia

Volumn 42, Issue 11, 1999, Pages 1293-1301

  Jonsson B ^a   Cook, J R ^b   Pedersen, T R ^c  

^a STOCKHOLM SCHOOL OF ECONOMICS   (Sweden)

^b MERCK RESEARCH LABORATORIES   (United States)

^c AKER UNIVERSITY HOSPITAL   (Norway)

Author keywords

Cholesterol; Cost effectiveness; Lipid lowering; Scandinavian Simvastatin Survival Study (4S)

Indexed keywords

SIMVASTATIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; FEMALE; GLUCOSE BLOOD LEVEL; HOSPITAL ADMISSION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERLIPIDEMIA; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; SWEDEN; TREATMENT OUTCOME; UNITED STATES;

ADULT; AGED; ANTILIPEMIC AGENTS; CORONARY DISEASE; COST-BENEFIT ANALYSIS; DIABETIC ANGIOPATHIES; DRUG COSTS; FEMALE; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PROBABILITY; PROGNOSIS; PROSPECTIVE STUDIES; SIMVASTATIN; SURVIVAL ANALYSIS;

EID: 0032710822     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001250051441     Document Type: Article

References (23)

1. 1. Rubin RJ, Altman WM, Mendelson DN (1995) Health care expenditures for people with diabetes mellitus. Diabetes Spect 8: 3
2. 2. American Diabetes Association (1987) Direct and indirect costs of diabetes in the United States in 1987. Alexandria, VA ADA
3. 3. Ray NF, Willis S, Thamer M (1993) Direct and indirect costs of diabetes in the United States in 1992. Alexandria, VA ADA
4. 4. Huse D M, Oster G, Killen R, Lacey M, Colditz, G (1989) The economic cost of non-insulin dependent diabetes mellitus. JAMA 262: 2708-2713
5. 5. American Diabetes Association (1998) Economic consequences of diabetes mellitus in the U.S. in 1997. Diabetes Care 21: 296-309
6. 6. Jönsson B (1983) Diabetes: the cost of illness and the cost of control. Acta Med Scand, 671 (Suppl):19-27
7. 7. Henriksson F, Jönsson B (1998) Diabetes: the cost of illness in Sweden. Journal of Internal Medicine 244: 461-468
8. 8. Herlitz J, Malmberg K, Karlsson BW, Ryden L, Hjalmarsson Å (1988) Mortality and morbidity during five-year follow-up of diabetes with myocardial infraction. Acta Med Scand 224: 31-38
9. 9. Karlsson BW, Herlitz J, Hjalmarsson Å (1993) Prognosis of acute myocardial infarction in diabetic and non-diabetic patients. Diabet Med 10: 449-454
10. 10. Pyorala K, Pedersen T, Kjekshus J et al. (1997) Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. Diabetes Care 20: 614-620
11. 11. Haffner S, Alexander CM, Cook TJ et al. (1999) Reduced coronary events in simvastatin-treated subjects with coronary heart disease and diabetes or impaired fasting glucose: subgroup analysis in the Scandinavian Simvastatin Survival Study (4S). Arch Int Med (In press)
12. 12. Jönsson B, Johannesson M, Kjekshus J, Olsson AG, Pedersen TR, Wedel H for the Scandinavian Simvastatin Survival Study Group (1996) Cost effectiveness of cholesterol lowering: results from the Scandinavian Simvastatin Survival Study (4S). Eur Heart J 17: 1001-1007
13. 13. Johannesson M, Jönsson B, Kjekshus J, Olsson AG, Pedersen TR, Wedel H for the Scandinavian Simvastatin Survival Study Group (1997) Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. N Engl J Med 336: 332-336
14. 14. Pedersen T, Kjekshus J, Berg K et al. (1996) Cholesterol lowering and the use of healthcare resources: results of the Scandinavian Simvastatin Survival Study. Circulation. 93: 1796-1802
15. 15. Statistics Sweden. Statistical Yearbook of Sweden 1995, 51-52 (official publication)
16. 16. Malmberg K, Ryden L, Efendic S et al. (1995) A randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction: effects on one year mortality(DIA-GAMI study). JACC 26: 57-65
17. 17. Olsson G, Rehnqvist N, Sjogren A, Erhardt L, Lundman T (1985): Long-term treatment with metoprolol after myocardial infarction: effect on 3-year mortality and morbidity. JACC 5: 1428-1437
18. 18. Hedbäck B, Perk J (1987) 5-year results of a comprehensive rehabilitation programme after myocardial infarction. Eur Heart J 8: 234-242
19. 19. Efron B, Gong G (1983) A leisurely look at the bootstrap, jackknife and cross-validation. The American Statistician. 37: 36-48
20. 20. Johannesson M, Meltzer D (1998) Some reflections on cost-effectiveness analysis. Health Economics 7: 1-8
21. 21. Polsky D, Glick HA, Wilke R, Schulman K(1997) Confidence intervals for cost-effectiveness ratios: a comparison of four methods. Health Economics 6: 243-252
22. 22. DCCT Research Group (1996) Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial. JAMA 276: 1409-1415
23. 23. Eastman RC, Javitt JC, Herman WH et al. (1997) Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care 20: 735-744